A novel monoclonal human antibody specific to the cell-surface exposed protein EphA2, which is over-expressed in many forms of cancer and is a validated therapeutic target.
Many forms of cancer, most notably basal-like breast cancers, induce the over-expression of a cell-surface exposed protein EphA2, making it a potent biomarker for cancer diagnosis as well as a therapeutic target. Using a unique, high-throughput phage-display screening approach, UCSF researchers have successfully identified a novel human monoclonal antibody that recognizes a new epitope of EphA2, and upon recognizing EphA2 on the cell surface is able to be efficiently internalized. Internalizing antibodies are essential technologies for the targeted delivery of anti-cancer drugs.
This novel invention provides the following advantages:
UCSF researchers have taken a high-throughput screening approach to identify novel human antibodies against cell-surface proteins commonly over-expressed in cancer cells. The approach involves rounds of selection of a human antibody phage-display library for internalization in a human breast cancer cell line, and further enrichment of antibodies that bind human proteins of interest by expressing them (in their surface-displayed form) in yeast. The result of this approach has produced a novel human antibody against the validated cancer target EphA2.
To develop and commercialize this novel antibody as a research tool for the study of, diagnosis of, or therapy for certain forms of cancer.
|United States Of America||Issued Patent||10,406,225||09/10/2019||2009-106|
|United States Of America||Issued Patent||9,446,125||09/20/2016||2009-106|
|Russian Federation||Issued Patent||2598711||09/06/2016||2009-106|
|United States Of America||Issued Patent||9,220,772||12/29/2015||2009-106|
|South Africa||Issued Patent||2013/00573||03/26/2014||2009-106|